Piper Sandler raised the firm’s price target on Viatris to $11 from $10 and keeps a Neutral rating on the shares. The firm does not envision a scenario entailing a re-rating of valuation multiple given the relative lack of visibility into significant EBITDA growth over time and capital structure realities to consider.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTRS:
- Viatris no bargain despite being cheapest S&P 500 stock, Barron’s says
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 20-24, 2023
- Viatris, Theravance announce top-line results from YUPELRI Phase III trial
- Viatris, Theravance Biopharma announce results from YUPELRI
- Viatris lowers FY23 revenue view to $15.4B-$15.6B from $15.5B-$16.0B
